Indication:
Metastatic hormone-sensitive prostate cancer (mHSPC)
Status:
The Phase III study ARANOTE is ongoing (2021-) The study evaluates darolutamide in combination with hormonal therapy (androgen deprivation therapy) in patients with metastatic hormone sensitive prostate cancer.
Primary outcome measures:
Radiological progression-free survival
Secondary outcome measures:
Overall survival
Partner:
Bayer